News

Algeta partners with Avipep
Enlarge image

ResearchNorway

Algeta partners with Avipep

12.06.2013 - Norway’s cancer radiotherapy specialist Algeta has signed an agreement with Australian antibody developer Avipep Pty Ltd.

Under the terms of the agreement, the Algeta ASA will evaluate a conjugate that couples the Oslo-based company’s alpha-emitter thorium-227 to Avipep’s  Avibody, which targets a number of different solid tumour types. The thorium payload, which triggers DNA double-strand breaks that lead to cell death, have been shown to be highly localised, minimising off-target effects. Algeta has coupled the radionuclide to different cancer-targeting molecules such as Her2 and PDGFRβ

Avipep will provide access to one of its proprietary Avibodies, which the company uses for targeting and labelling tumour cells. Algeta will provide access to chelation and conjugation technologies, as well as to its alpha particle-emitting payload thorium-227. Both companies will contribute financially to the collaboration, which is expected to last for up to one year initially with the option for further cooperation thereafter. No further terms have been disclosed.  Algeta runs already collaborations with Genzyme and Affibody AB to develop Targeted Thorium Conjugates (TTC). After having brought its alpha-emitter radium-223 dichloride to the market, the company now seeks to evaluate targeted approaches of its technology. In contrast to cytotoxic payloads, TTC’s offer the advantage of not being subject to drug resistance.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/algeta-partners-with-avipep.html

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases.

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • ERYTECH PHARMA (F)39.50 EUR9.45%
  • PAION (D)2.69 EUR8.47%

FLOP

  • BAVARIAN NORDIC (D)40.26 EUR-10.69%
  • ZELTIA (E)3.69 EUR-8.44%
  • TIGENIX (B)0.73 EUR-7.59%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • DBV TECHNOLOGIES (F)81.03 EUR53.6%
  • IXICO (UK)34.00 GBP41.7%

FLOP

  • BIOTEST (D)27.24 EUR-60.8%
  • BIOTECH PHARMACON (N)9.43 NOK-46.1%
  • TRANSGENE (F)2.80 EUR-23.9%

TOP

  • ADOCIA (F)88.74 EUR587.4%
  • DBV TECHNOLOGIES (F)81.03 EUR328.7%
  • FORMYCON (D)28.70 EUR315.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.70 SEK-71.6%
  • NEOVACS (F)1.01 EUR-69.5%

No liability assumed, Date: 03.08.2015